GNTA

Genenta Science S.p.A. is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies for cancer treatment. The company's lead candidate Temferon utilizes genetically modified stem cells engineered to deliver therapeutic molecules directly to tumor sites upon engraftment. Genenta's proprietary platform technology involves harvesting a patient's own stem cells, genetically modifying them to produce anti-tumor agents, and reinfusing them to create a sustained internal drug delivery system. The company is advancing clinical trials for solid tumors with focus on glioblastoma and other difficult-to-treat cancers.